Glypican-3 is overexpressed in lung squamous cell carcinoma, but not in adenocarcinoma - PubMed (original) (raw)
Glypican-3 is overexpressed in lung squamous cell carcinoma, but not in adenocarcinoma
Sarit Aviel-Ronen et al. Mod Pathol. 2008 Jul.
Free article
Abstract
Glypican-3 is a membrane-bound proteoglycan whose expression has been linked to malignancies through the existence of both mutations and aberrant protein expression. Reports on glypican-3 expression in lung cancer were limited, with some evidence for loss of expression, which suggested a tumor-suppressor role. We sought to evaluate glypican-3 expression in lung cancer at the protein and mRNA levels and correlate it with clinical, histological and genomic characteristics such as RAS mutation status. We used immunohistochemistry on tissue microarray to study glypican-3 expression in 97 patients, evaluated glypican-3 mRNA levels by quantitative polymerase chain reaction in 143 patients and identified RAS mutations by allele-specific oligonucleotide hybridization. We correlated the results with clinical and histological data. Glypican-3 immunostaining was negative in all normal lung tissues, but positive in 23% of lung carcinoma samples. High protein and mRNA expression was associated with squamous histology (positive stain in 55% of squamous cell carcinoma vs 8% of adenocarcinoma, P<0.0001 for both immunostaining and mRNA). RAS mutations were highly associated with adenocarcinoma and low glypican-3 mRNA expression (P<0.0001 for both). Among smokers, glypican-3 mRNA expression was reduced in adenocarcinoma patients (P=0.013), and was elevated in those with squamous cell carcinoma (P=0.03, interaction P=0.0009). These opposing associations also correlated with the smoking burden. Patients with tumors staining positively for glypican-3 smoked significantly more than patients with tumors staining negatively (P=0.013). No association was found between glypican-3 expression and patient outcome. In conclusion, glypican-3 was overexpressed in cancerous compared with normal lung tissue. Adenocarcinoma and squamous cell carcinoma had differential expression of glypican-3, with predilection to squamous cell carcinoma patients who smoked. Glypican-3 expression in squamous cell carcinoma as an oncofetal protein renders it a potential candidate marker for early detection of lung squamous cell carcinoma.
Similar articles
- [Expression of glypican-3 in lung squamous cell carcinoma and adenocarcinoma and its relation with prognosis].
Li H, Deng Q, Huang L, Tang H, Cheng X. Li H, et al. Nan Fang Yi Ke Da Xue Xue Bao. 2013 Feb;33(2):212-5. Nan Fang Yi Ke Da Xue Xue Bao. 2013. PMID: 23443774 Chinese. - Differential expression of glypican-3 (GPC3) in lung squamous cell carcinoma and lung adenocarcinoma and its clinical significance.
Yu X, Li Y, Chen SW, Shi Y, Xu F. Yu X, et al. Genet Mol Res. 2015 Aug 28;14(3):10185-92. doi: 10.4238/2015.August.28.2. Genet Mol Res. 2015. PMID: 26345955 - High expression of folate receptor alpha in lung cancer correlates with adenocarcinoma histology and EGFR [corrected] mutation.
Nunez MI, Behrens C, Woods DM, Lin H, Suraokar M, Kadara H, Hofstetter W, Kalhor N, Lee JJ, Franklin W, Stewart DJ, Wistuba II. Nunez MI, et al. J Thorac Oncol. 2012 May;7(5):833-40. doi: 10.1097/JTO.0b013e31824de09c. J Thorac Oncol. 2012. PMID: 22729036 Free PMC article. - Discovery and diagnostic value of a novel oncofetal protein: glypican 3.
Wang SK, Zynger DL, Hes O, Yang XJ. Wang SK, et al. Adv Anat Pathol. 2014 Nov;21(6):450-60. doi: 10.1097/PAP.0000000000000043. Adv Anat Pathol. 2014. PMID: 25299314 Review. - Insulin-like growth factor II-messenger RNA-binding protein-3 and lung cancer.
Findeis-Hosey JJ, Xu H. Findeis-Hosey JJ, et al. Biotech Histochem. 2012 Jan;87(1):24-9. doi: 10.3109/10520295.2011.591831. Epub 2011 Aug 15. Biotech Histochem. 2012. PMID: 21838610 Review.
Cited by
- The use of therapeutic peptides to target and to kill cancer cells.
Boohaker RJ, Lee MW, Vishnubhotla P, Perez JM, Khaled AR. Boohaker RJ, et al. Curr Med Chem. 2012;19(22):3794-804. doi: 10.2174/092986712801661004. Curr Med Chem. 2012. PMID: 22725698 Free PMC article. Review. - Glypican-3 expression in malignant small round cell tumors.
Shibui Y, Miyoshi K, Kohashi K, Kinoshita Y, Kuda M, Yamamoto H, Taguchi T, Oda Y. Shibui Y, et al. Oncol Lett. 2019 Mar;17(3):3523-3528. doi: 10.3892/ol.2019.9976. Epub 2019 Jan 25. Oncol Lett. 2019. PMID: 30867793 Free PMC article. - Significant clinical response of progressive recurrent ovarian clear cell carcinoma to glypican-3-derived peptide vaccine therapy: two case reports.
Suzuki S, Shibata K, Kikkawa F, Nakatsura T. Suzuki S, et al. Hum Vaccin Immunother. 2014;10(2):338-43. doi: 10.4161/hv.27217. Epub 2013 Nov 21. Hum Vaccin Immunother. 2014. PMID: 24252799 Free PMC article. Clinical Trial. - In vivo fluorescence imaging of hepatocellular carcinoma using a novel GPC3-specific aptamer probe.
Zhao M, Dong L, Liu Z, Yang S, Wu W, Lin J. Zhao M, et al. Quant Imaging Med Surg. 2018 Mar;8(2):151-160. doi: 10.21037/qims.2018.01.09. Quant Imaging Med Surg. 2018. PMID: 29675356 Free PMC article. - Overexpression of glypican-3 is a predictor of poor prognosis in hepatocellular carcinoma: An updated meta-analysis.
Zhang J, Zhang M, Ma H, Song X, He L, Ye X, Li X. Zhang J, et al. Medicine (Baltimore). 2018 Jun;97(24):e11130. doi: 10.1097/MD.0000000000011130. Medicine (Baltimore). 2018. PMID: 29901640 Free PMC article. Review.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical